CT62: A Potential Drug Target and Biomarker (G196993)

Target Name: CT62

NCBI ID: G196993

CT62

Other Name(s): CT62_HUMAN | cancer/testis associated 62 | Cancer/testis antigen 62

CT62: A Potential Drug Target and Biomarker

CT62, also known as 62-mercaptoethanesulfonic acid, is a compound that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and chemical properties make it an attractive candidate for drug development.

The drug industry is constantly searching for new and innovative compounds that can be used to treat various diseases. CT62 is one of these compounds, which has been shown to have a unique mechanism of action that can lead to the inhibition of the development of cancer cells.

CT62 is a broad-spectrum inhibitor of cell signaling pathways, including the TGF-β pathway. This pathway is involved in the development and maintenance of tissues, including cancer. The inhibition of this pathway can lead to the inhibition of cell proliferation and the inhibition of the formation of new blood vessels, which can be beneficial in the treatment of cancer.

In addition to its potential use in cancer treatment, CT62 has also been shown to be a potential biomarker for the disease. The development of new biomarkers for diseases is a critical area of research, as they can help doctors to diagnose and treat diseases more accurately and efficiently.

CT62 has been shown to be able to bind to a variety of different proteins, including the TGF-β receptor. This receptor is involved in the development and maintenance of tissues, including cancer. The binding of CT62 to this receptor has been shown to lead to the inhibition of the development of cancer cells.

Furthermore, CT62 has also been shown to be able to inhibit the activity of the transcription factor, NF-kappa-B. This factor is involved in the regulation of various cellular processes, including cell growth and differentiation. The inhibition of NF-kappa-B has been shown to lead to the inhibition of the development of cancer cells.

In conclusion, CT62 is a compound that has the potential to be a drug target and biomarker for various diseases. Its unique structure and chemical properties make it an attractive candidate for drug development. Further research is needed to fully understand its potential mechanisms of action and to determine its safety and efficacy as a drug.

Protein Name: Cancer/testis Associated 62

The "CT62 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT62 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets